{
  "stage": "S3",
  "passed": false,
  "convergence_score": 0.811,
  "convergence_threshold": 0.85,
  "convergence_pass": false,
  "jaccard": 0.3257,
  "jaccard_threshold": 0.85,
  "jaccard_pass": false,
  "type_01_ratio": 0.5294,
  "type_01_threshold": 0.75,
  "type_pass": false,
  "cosine": 0.811,
  "jsd": 0.2492,
  "kappa": 0.9081,
  "type_distribution": {
    "0": 0.0,
    "1": 0.5294117647058824,
    "2": 0.23529411764705882,
    "3": 0.23529411764705882
  },
  "divergence_map": {
    "total_unique_claims": 19,
    "most_divergent": [
      {
        "statement": "At \u22642.5 mg/day oral THC, peak brain CB1 occupancy reaches ~15-25%, sufficient for G-protein signaling (EC50 ~5-10 nM) but below \u03b2-arrestin recruitment threshold (EC50 ~50-100 nM for \u03949-THC), preserving receptor surface expression.",
        "models_supporting": [
          "claude"
        ],
        "types_assigned": [
          1
        ],
        "confidences": [
          0.72
        ],
        "type_variance": 0,
        "n_supporters": 1
      },
      {
        "statement": "Low-dose THC augments rather than displaces endocannabinoid tone because at 15-25% occupancy, sufficient unoccupied CB1 remains for 2-AG/AEA signaling, and THC may inhibit FAAH at low concentrations (Ki ~5-15 \u03bcM range), mildly elevating AEA.",
        "models_supporting": [
          "claude"
        ],
        "types_assigned": [
          2
        ],
        "confidences": [
          0.55
        ],
        "type_variance": 0,
        "n_supporters": 1
      },
      {
        "statement": "The tolerance crossover point is governed by first-order kinetics: therapeutic window persists while k_recycle + k_synthesis > k_int \u00d7 fractional_occupancy. For CB1, k_recycle \u2248 0.02 min\u207b\u00b9, k_int \u2248 0.05 min\u207b\u00b9 at full occupancy. Crossover occurs at ~40-50% sustained occupancy, corresponding to ~10-15 mg/day chronic dosing.",
        "models_supporting": [
          "claude"
        ],
        "types_assigned": [
          3
        ],
        "confidences": [
          0.45
        ],
        "type_variance": 0,
        "n_supporters": 1
      },
      {
        "statement": "HPA axis recalibration via PVN CB1 is a primary mediator of sustained wellbeing, reducing tonic CRH release by ~20-35% over 2-4 weeks, measurable as decreased morning cortisol AUC.",
        "models_supporting": [
          "claude"
        ],
        "types_assigned": [
          1
        ],
        "confidences": [
          0.62
        ],
        "type_variance": 0,
        "n_supporters": 1
      },
      {
        "statement": "1:** Chronic low-dose THC (\u22642.5 mg/day) improves wellbeing via *biphasic CB1 signaling*: G-protein activation (EC50 ~10 nM) dominates at 10\u201330% occupancy, while \u03b2-arrestin recruitment (EC50 >100 nM) is avoided, preserving cAMP/PKA tone.",
        "models_supporting": [
          "mistral"
        ],
        "types_assigned": [
          1
        ],
        "confidences": [
          0.85
        ],
        "type_variance": 0,
        "n_supporters": 1
      },
      {
        "statement": "2:** The therapeutic index (TD50/ED50) for wellbeing vs. tolerance exceeds 10, with tolerance emerging at ~25 mg/day due to CB1 internalization exceeding recycling/synthesis rates (k_int > k_rec).",
        "models_supporting": [
          "mistral"
        ],
        "types_assigned": [
          0
        ],
        "confidences": [
          0.75
        ],
        "type_variance": 0,
        "n_supporters": 1
      },
      {
        "statement": "3:** Sustained wellbeing requires *synergistic 2-AG signaling*: low-dose THC (\u22642.5 mg/day) adds to tonic 2-AG without displacement, while high-dose THC (>10 mg/day) saturates CB1, reducing 2-AG access and upregulating MAGL.",
        "models_supporting": [
          "mistral"
        ],
        "types_assigned": [
          1
        ],
        "confidences": [
          0.7
        ],
        "type_variance": 0,
        "n_supporters": 1
      },
      {
        "statement": "4:** HPA axis recalibration via CB1 in PVN/amygdala involves *glutamatergic constraint*: tonic CB1 activation reduces excitatory drive to CRH neurons, lowering cortisol set-point over 2\u20134 weeks.",
        "models_supporting": [
          "mistral"
        ],
        "types_assigned": [
          1
        ],
        "confidences": [
          0.65
        ],
        "type_variance": 0,
        "n_supporters": 1
      },
      {
        "statement": "5 (SINGULAR):** The \"critical threshold\" for tolerance is a *kinetic inflection point* where THC-driven CB1 internalization (k_int) equals receptor recycling + de novo synthesis (k_rec + k_syn), occurring at ~30% occupancy.",
        "models_supporting": [
          "mistral"
        ],
        "types_assigned": [
          3
        ],
        "confidences": [
          0.6
        ],
        "type_variance": 0,
        "n_supporters": 1
      },
      {
        "statement": "CB1 occupancy by chronic low-dose THC (2.5mg/day, steady-state plasma ~2ng/mL or 6nM) is 10-25% (occupancy = [THC]/( [THC] + Kd=40nM), Hill n=1), enhancing 2-AG efficacy without saturating.",
        "models_supporting": [
          "grok"
        ],
        "types_assigned": [
          1
        ],
        "confidences": [
          0.82
        ],
        "type_variance": 0,
        "n_supporters": 1
      }
    ],
    "models_present": [
      "claude",
      "mistral",
      "grok",
      "gemini",
      "deepseek"
    ]
  },
  "recommendation": "S3 gate FAILED. The system did not converge to stable consensus. This indicates genuine scientific disagreement worth investigating. Review the divergence map below."
}